EUVIMEDEUVIMED entdecken
Crossref

Risk stratification and potential overtreatment in adjuvant CDK4/6 inhibitor trials: do all patients with Stage II disease and favorable biology derive benefit?

Patrick Neven, Francois Duhoux, Philippe Aftimos, Patrick Berteloot, Evandro de Azambuja, Cleo De Backer, Debbie Debaere, Françoise Derouane, Christel Fontaine, Sileny Han, Greet Huygh, Michail Ignatiadis und 8 weitere

European Journal of Cancer · 2026-12 · 249 · 117808

DOI: 10.1016/j.ejca.2026.117808 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026-12. Verfasst von Patrick Neven und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynaecological Oncology, University Hospitals Leuven, Leuven, Belgium. Electronic address: patrick.neven@uzleuven.be. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

AbemaciclibAdjuvant therapyBreast neoplasmsCDK 4/6iCyclin-dependent kinase 4 and 6 inhibitorsHormone receptor-positive breast cancerRibociclibRisk assessmentRisk stratificationShared decision making

Autor:innen und Institutionen

  • Department of Gynaecological Oncology, University Hospitals Leuven, Leuven, Belgium. Electronic address: patrick.neven@uzleuven.be.
  • Department of Medical Oncology, University Hospitals Saint-Luc, UC Louvain, Brussels, Belgium.
  • Department of Medical Oncology, Institut Jules Bordet, Brussels, Belgium.
  • Breast Clinic, AZ Sint-Maarten, Mechelen, Belgium.
  • Department of Oncology, AZ Turnhout, Turnhout, Belgium.
  • Department of Oncology, Jan Yperman Ziekenhuis, Ieper, Belgium.

Zitieren

APA

Neven, P., Duhoux, F., Aftimos, P., Berteloot, P., de Azambuja, E., De Backer, C., Debaere, D., Derouane, F., Fontaine, C., Han, S., Huygh, G., Ignatiadis, M., Naert, E., Punie, K., Requilé, A., Sotiriou, C., Tjalma, W., Traen, K., Van Herck, Y., & Wildiers, H. (2026). Risk stratification and potential overtreatment in adjuvant CDK4/6 inhibitor trials: do all patients with Stage II disease and favorable biology derive benefit?. European Journal of Cancer, 249, 117808. https://doi.org/10.1016/j.ejca.2026.117808

Vancouver

Neven P, Duhoux F, Aftimos P, Berteloot P, de Azambuja E, De Backer C, et al. Risk stratification and potential overtreatment in adjuvant CDK4/6 inhibitor trials: do all patients with Stage II disease and favorable biology derive benefit?. European Journal of Cancer. 2026;249:117808. doi:10.1016/j.ejca.2026.117808

BibTeX
@article{Neven2026,
  author = {Neven, Patrick and Duhoux, Francois and Aftimos, Philippe and Berteloot, Patrick and de Azambuja, Evandro and De Backer, Cleo and Debaere, Debbie and Derouane, Françoise and Fontaine, Christel and Han, Sileny and Huygh, Greet and Ignatiadis, Michail and Naert, Eline and Punie, Kevin and Requilé, Annelies and Sotiriou, Christos and Tjalma, Wiebren and Traen, Koen and Van Herck, Yannick and Wildiers, Hans},
  title = {Risk stratification and potential overtreatment in adjuvant CDK4/6 inhibitor trials: do all patients with Stage II disease and favorable biology derive benefit?},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {249},
  pages = {117808},
  doi = {10.1016/j.ejca.2026.117808}
}
Kostenlos starten →